Partnerships

Pandemic Preparedness

Pandemic Preparedness

Partnership website: https://beready4pandemics.eu/

This Partnership will serve as a coordinated, long-termframework to strengthen Europe’s capacity to respond to health crises. The partnership is currently under preparation.

The European Partnership for Pandemic Preparedness aims to improve the EU’s preparedness to predict, prevent and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national and regional level. The preparatory actions BE READY and BE READY PLUS are building the foundation for the future partnership expected to be launched beginning of 2026.  

The preparatory action BE READY PLUS kicked off in April 2025 with the aim to translate research priorities into actionable steps through a call topic selection strategy aligned with the SRIA. BE READY PLUS will lay the groundwork for early actions, ensuring that the partnership is fully prepared to implement the SRIA from its first annual workplan.


Timeline & key documents

Contact

BE READY project coordinator: information@anrs.fr

Commission services: RTD-COMBATTING-DISEASES@ec.europa.eu

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

More detailed info Overview of partnerships

How to use partnerships?

  • orientation
    Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.
  • networking
    Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.
  • ecosystem analysis
    Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.
  • steering the agenda
    Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.
Author Do you have an additional question? Or spotted a mistake? Don't hesitate to contact me!
Image of Sarah Stroobants
Sarah Stroobants

sarah.stroobants@fwo.be

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article Check out the other testimonials 
Logo of FWO
Logo of VLAIO

NCP Flanders

Updates

Our Services

Legal mentions

Privacy Policy
Cookies

LinkedIn